Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728921 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL17718444 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL16273305 | 0.94 | KDM1A (0.88) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL16273397 | 0.94 | KDM1A (0.88) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL17712531 | 0.90 | KDM1A (0.81) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL16273386 | 0.89 | KDM1A (0.80) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL16273381 | 0.89 | KDM1A (0.80) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL16273303 | 0.89 | KDM1A (0.80) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL16273302 | 0.89 | KDM1A (0.80) | KDM1AMAOBMAOAELANESMN1; SMN2 | |
| SCHEMBL19976248 | 0.88 | KDM1A (0.79) | KDM1AMAOBMAOAELANESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210686-A1 | LSD1 INHIBITORS FOR USE IN THE TREATMENT AND PREVENTION OF FIBROSIS OF TISSUES | Université d'Aix-Marseille (FR) | 2023-07-19 | — | — | EP | claimed |
| WO-2022053520-A1 | LSD1 INHIBITORS FOR USE IN THE TREATMENT AND PREVENTION OF FIBROSIS OF TISSUES | UNIVERSITÉ D'AIX MARSEILLE (FR) | 2022-03-17 | — | — | WO | claimed |
| EP-3964204-A1 | LSD1 INHIBITORS FOR USE IN THE TREATMENT AND PREVENTION OF FIBROSIS OF TISSUES | Université d'Aix-Marseille (FR) | 2022-03-09 | — | — | EP | claimed |
| WO-2025235516-A1 | DEVELOPMENT OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS AS ANTI-CANCER REAGENTS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4210686-A1 | LSD1 INHIBITORS FOR USE IN THE TREATMENT AND PREVENTION OF FIBROSIS OF TISSUES | Université d'Aix-Marseille (FR) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022053520-A1 | LSD1 INHIBITORS FOR USE IN THE TREATMENT AND PREVENTION OF FIBROSIS OF TISSUES | UNIVERSITÉ D'AIX MARSEILLE (FR) | 2022-03-17 | — | — | WO | disclosed |
| EP-3964204-A1 | LSD1 INHIBITORS FOR USE IN THE TREATMENT AND PREVENTION OF FIBROSIS OF TISSUES | Université d'Aix-Marseille (FR) | 2022-03-09 | — | — | EP | disclosed |
| EP-3003301-B1 | NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA LAS VEGAS (US) | 2021-02-24 | — | — | EP | disclosed |
| US-9918983-B2 | Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160120862-A1 | Novel Suicidal LSD1 Inhibitors Targeting SOX2-Expressing Cancer Cells | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2016-05-05 | — | — | US | disclosed |
| US-20160120862-A1 | Novel Suicidal LSD1 Inhibitors Targeting SOX2-Expressing Cancer Cells | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2016-05-05 | — | — | US | disclosed |
| WO-2014194280-A2 | NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS | The Board of Regents of the Nevada System of Higher Education on behalf of the University of (US) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120862-A1 | Novel Suicidal LSD1 Inhibitors Targeting SOX2-Expressing Cancer Cells | HDAC1, KDM1B, KDM1A | KDM1A 3/4885MAOB 419/4885MAOA 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.